Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

According to Benzinga Pro, Pfizer Inc's peer group average for short interest as a percentage of float is 3.63%, which means ...

Abstract: Investment is a crucial driver of economic growth and a fundamental component of Gross Domestic Product (GDP). Accurate investment forecasting is essential for informed policymaking and ...

The investment case for pharmaceutical giant Pfizer is presenting a complex puzzle. Conflicting signals are creating a stark ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Market analysts are pointing to substantial growth potential for Pfizer Inc. following a challenging period for the pharmaceutical giant. While many investor ...

Arvinas shows strong ESR1-mutant data with limited scope, niche SERD competition, Pfizer uncertainty, and a high-risk pipeline. See why ARVN stock is a hold.

President Donald Trump often proclaims that he’s brought the US a historic investment boom, drawing pledges he says will reach $21 trillion by the end of the year from governments and companies eager ...